相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
Sean A. Dilliard et al.
Nature Reviews Materials (2023)
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Hirohito Yamaguchi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
Alexander C. Huang et al.
NATURE IMMUNOLOGY (2022)
HSP70-Promoter-Driven CRISPR/Cas9 System Activated by Reactive Oxygen Species for Multifaceted Anticancer Immune Response and Potentiated Immunotherapy
Liang Zhao et al.
ACS NANO (2022)
Nanodelivery of nucleic acids
Barbara B. Mendes et al.
NATURE REVIEWS METHODS PRIMERS (2022)
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Mukaddes Izci et al.
CHEMICAL REVIEWS (2021)
Molecular and evolutionary processes generating variation in gene expression
Mark S. Hill et al.
NATURE REVIEWS GENETICS (2021)
Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy
Cheng-Tao Jiang et al.
NATURE COMMUNICATIONS (2021)
Chemokines and the immune response to cancer
Aleksandra J. Ozga et al.
IMMUNITY (2021)
The current landscape of nucleic acid therapeutics
Jayesh A. Kulkarni et al.
NATURE NANOTECHNOLOGY (2021)
Turning cold tumors into hot tumors by improving T-cell infiltration
Yuan-Tong Liu et al.
THERANOSTICS (2021)
A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
Yu Chen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing
Qiang Cheng et al.
NATURE NANOTECHNOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics
Xiao Han et al.
ACCOUNTS OF CHEMICAL RESEARCH (2020)
An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy
Jiyoon Bu et al.
NANO LETTERS (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
The once and future gene therapy
Karen Bulaklak et al.
NATURE COMMUNICATIONS (2020)
Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters
Mariela Montano-Samaniego et al.
FRONTIERS IN ONCOLOGY (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model
Chuanjian Wu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora et al.
ADVANCES IN THERAPY (2019)
Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles
Ying-Li Luo et al.
ACS NANO (2018)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Chao Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Delivery Strategies for Immune Checkpoint Blockade
Qian Chen et al.
ADVANCED HEALTHCARE MATERIALS (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles
Parisa Foroozandeh et al.
NANOSCALE RESEARCH LETTERS (2018)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
Purnima Bhat et al.
CELL DEATH & DISEASE (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Jung Soo Suk et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade (vol 29, pg 285, 2016)
Haidong Tang et al.
CANCER CELL (2016)
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Sam Chen et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination
Yi-Nan Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Chao Wang et al.
NANO LETTERS (2016)
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
Chunbai He et al.
NATURE COMMUNICATIONS (2016)
T cell migration, search strategies and mechanisms
Matthew F. Krummel et al.
NATURE REVIEWS IMMUNOLOGY (2016)
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Juan Fu et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
A novel recombinant protein of IP10-EGFRvIIIscFv and CD8+ cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice
Xuan Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Survivin: A new target for anti-cancer therapy
Brid M. Ryan et al.
CANCER TREATMENT REVIEWS (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma
R. Zhang et al.
GENE THERAPY (2006)
Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition
S Cornélie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter
ZB Zhu et al.
CANCER GENE THERAPY (2004)
Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts
AL Feldman et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
